|

PD1/PDL1 antibody monotherapy, up to 24 weeks Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Peking University1

Indications

  • DMMR Cancer1
  • MSI-H1
  • Colon Cancer1
  • Gastric Cancer1
  • Cancer1

Other1 trial

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.